Corient Private Wealth LLC Buys 3,160 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Corient Private Wealth LLC lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 140.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,404 shares of the company’s stock after purchasing an additional 3,160 shares during the quarter. Corient Private Wealth LLC’s holdings in Vaxcyte were worth $442,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Diversified Trust Co bought a new position in Vaxcyte in the fourth quarter worth approximately $1,433,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vaxcyte by 23.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company’s stock worth $2,163,000 after purchasing an additional 4,962 shares in the last quarter. TimesSquare Capital Management LLC grew its position in Vaxcyte by 53.7% in the 4th quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company’s stock valued at $33,860,000 after purchasing an additional 144,516 shares during the period. Principal Financial Group Inc. increased its stake in Vaxcyte by 186.2% during the 3rd quarter. Principal Financial Group Inc. now owns 52,702 shares of the company’s stock valued at $6,022,000 after purchasing an additional 34,287 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Vaxcyte by 70.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company’s stock worth $49,418,000 after buying an additional 246,049 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Teri Loxam sold 6,250 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now directly owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $17,208,443.70. This trade represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,250 shares of company stock worth $3,840,018. Insiders own 3.10% of the company’s stock.

Vaxcyte Stock Down 1.9 %

Shares of NASDAQ PCVX opened at $69.46 on Friday. The company has a market capitalization of $8.94 billion, a PE ratio of -15.10 and a beta of 1.02. The stock’s 50 day moving average price is $80.07 and its 200-day moving average price is $92.52. Vaxcyte, Inc. has a twelve month low of $58.10 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. As a group, research analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PCVX. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a report on Friday, December 20th. They set a “buy” rating and a $135.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, Guggenheim restated a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.